Αποτελέσματα Αναζήτησης
TYSABRI ® (natalizumab) is available only through the TOUCH Prescribing Program TYSABRI Outreach: Unified Commitment to Health. TOUCH On-Line is a web-based tool designed to assist TOUCH Prescribing Program participants in fulfilling their TOUCH Prescribing Program Requirements.
- Touch On-Line
TOUCH On-Line is a web-based tool designed to assist TOUCH...
- How to Enroll
TOUCH On-Line. How do I enroll in the TOUCH Prescribing...
- Touch On-Line
TOUCH On-Line is a web-based tool designed to: Provide real-time access to data for patients taking TYSABRI. Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites.
TOUCH On-Line. How do I enroll in the TOUCH Prescribing Program? Prescribers, infusion sites, certified pharmacies associated with infusion sites and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense or receive TYSABRI. Infusion Sites. Certified Pharmacies.
Helpful Information for the Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI. Understanding PML for Gastroenterologists material is a resource for Gastroenterologists, Internists, or other non-Neurology specialists treating TYSABRI patients.
TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
• TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program
•TYSABRI®(natalizumab) is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. •TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
